Health Encyclopedia

Pipracil

Pipracil: Uses, Side Effects, Dosage, Interactions

Introduction

Pipracil, also known as piperacillin sodium, is a broad-spectrum β-lactam antibiotic belonging to the ureidopenicillin class. It is commonly used in combination with tazobactam, a β-lactamase inhibitor, to treat various bacterial infections. Pipracil is administered intravenously and is effective against both gram-positive and gram-negative bacteria. This article provides a comprehensive overview of Pipracil, including its uses, side effects, dosage, and interactions.

Mechanism of Action

Pipracil works by inhibiting the synthesis of bacterial cell walls, ultimately leading to cell death. As a penicillin derivative, it binds to and inactivates penicillin-binding proteins (PBPs), enzymes essential for the cross-linking of peptidoglycan chains in bacterial cell walls [1]. The combination of Pipracil with tazobactam enhances its effectiveness against β-lactamase-producing bacteria, as tazobactam irreversibly inhibits a wide range of β-lactamases [2].

Medical Uses

Pipracil is prescribed for the treatment of various bacterial infections, including:

It is also used for surgical prophylaxis to prevent postoperative infections. Pipracil‘s broad spectrum of activity makes it a valuable option for empiric therapy in critically ill patients [3].

Dosage Information

The recommended dosage of Pipracil depends on the type and severity of the infection, as well as the patient’s age and renal function. The usual adult dose ranges from 3 to 4 grams every 4-6 hours, administered as an intravenous infusion over 20-30 minutes. Dosage adjustments may be necessary for patients with renal impairment or those undergoing hemodialysis [4].

Side Effects

Common side effects of Pipracil include:

Rare but severe side effects may include anaphylaxis, Stevens-Johnson syndrome, and Clostridium difficile-associated diarrhea. Monitoring for adverse reactions and prompt intervention is essential to minimize the risk of serious complications [5].

Drug Interactions

Pipracil may interact with several medications, including:

Careful monitoring and dose adjustments may be necessary when Pipracil is co-administered with these drugs [6].

armacodynamics-and-pharmacokinetics”>Ph armacodynamics and armacokinetics/”>Ph armacokinetics

Pipracil exhibits time-dependent bactericidal activity, with its effectiveness primarily determined by the duration of time the drug concentration remains above the minimum inhibitory concentration (MIC) for the target pathogen. It is predominantly eliminated by renal excretion, with a half-life of approximately 1 hour in patients with normal renal function [7].

Special Considerations

Pipracil should be used with caution in pregnant women (Category B) and only when the benefits outweigh the risks. It is excreted in breast milk and may cause diarrhea or allergic reactions in nursing infants. Dosage adjustments are necessary for pediatric patients and those with renal impairment. Elderly patients may be more susceptible to adverse effects due to age-related changes in renal function [4].

Contraindications and Precautions

Pipracil is contraindicated in patients with a history of severe hypersensitivity reactions to penicillins, cephalosporins, or beta-lactamase inhibitors. Precautions should be taken in patients with a history of gastrointestinal diseases, particularly colitis, as Pipracil may increase the risk of Clostridium difficile-associated diarrhea [4].

Historical and Regulatory Information

Pipracil was first approved by the U.S. Food and Drug Administration (FDA) in 1981 and has since been marketed under various brand names, such as PIPRACIL® and Zosyn®. The combination of piperacillin and tazobactam was approved in 1993, offering enhanced activity against β-lactamase-producing bacteria [8].

Research and Studies

Numerous clinical trials have investigated the efficacy and safety of Pipracil in various clinical settings. A randomized controlled trial by Solomkin et al. demonstrated the non-inferiority of Pipracil compared to meropenem in the treatment of complicated intra-abdominal infections [9]. Ongoing research focuses on optimizing dosing strategies and evaluating the effectiveness of Pipracil against emerging multidrug-resistant pathogens.

Comparative Analysis

Pipracil, in combination with tazobactam, has a broader spectrum of activity compared to other ureidopenicillins, such as mezlocillin and azlocillin. It is often considered a first-line option for empiric therapy in critically ill patients due to its effectiveness against both gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa [3].

Patient Information

Patients should be advised to complete the prescribed course of Pipracil, even if their symptoms improve, to prevent the development of antibiotic resistance. They should be informed about the potential side effects and instructed to contact their healthcare provider if they experience severe or persistent adverse reactions. Patients should also be counseled on the importance of maintaining adequate hydration and reporting any signs of allergic reactions or Clostridium difficile-associated diarrhea [4].

Storage and Handling

Pipracil should be stored at room temperature (20°C to 25°C) and protected from light. Reconstituted solutions are stable for 24 hours at room temperature or 48 hours when refrigerated (2°C to 8°C). Healthcare professionals should follow aseptic techniques when preparing and administering Pipracil solutions to minimize the risk of contamination [4].

Bibliography and Further Reading

  1. Wise, R., Andrews, J.M., & Bedford, K.A. (1978). Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. Journal of Antimicrobial Chemotherapy, 4(suppl_B), 59-64.
  2. Bush, K., Macalintal, C., Rasmussen, B.A., Lee, V.J., & Yang, Y. (1993). Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrobial Agents and Chemotherapy, 37(4), 851-858.
  3. Schentag, J.J., & Ballow, C.H. (1991). Tissue-directed ph armacokinetics. The American Journal of Medicine, 91(3), S5-S11.
  4. Zosyn (piperacillin and tazobactam for injection, USP) [package insert]. (2017). Pfizer Inc.
  5. Azimi, E., Reddy, V.B., & Lerner, E.A. (2020). Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN). PubMed. StatPearls Publishing.
  6. Rao, Y., & Herold, K.A. (2021). Aminoglycoside And Penicillin Antibiotics. PubMed. StatPearls Publishing.
  7. Veiga, R.P., & Paiva, J.A. (2018). armacokinetics/”>Ph armacokinetics-ph armacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients. Critical Care, 22(1), 1-34.
  8. Zosyn NDA 050684 Approval Package. (1993). U.S. Food and Drug Administration.
  9. Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., … & Eckmann, C. (2010). Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clinical Infectious Diseases, 60(10), 1462-1471.
Pipracil